Alan M Ducatman

Alan M Ducatman, a sole proprietor operating as a medical expert witness and case reviewer, delivers expert testimony and medical case review services to federal health and justice agencies exclusively as a prime contractor under small business set-asides and full-and-open competitive procurements. Based in Parkland, Florida, Ducatman operates under primary NAICS 621111 (Offices of Physicians, except Mental Health Specialists) and secondary NAICS 541900 (All Other Legal Services), with a fourteen-award portfolio spanning twelve years that totals $8.2 million in combined potential value.

Ducatman's customer concentration is narrow and stable. The Department of Health and Human Services Health Resources and Services Administration (HRSA) Headquarters accounts for 100% of repeat work and dominates the portfolio with twelve awards valued at $7.9 million combined potential value, all supporting the Vaccine Injury Compensation Program (VICP) through medical case review and expert testimony. The Department of Justice Environment and Natural Resources Division has placed two awards valued at $294 thousand for expert witness services. The two customers account for 100% of awards by count and dollar value. HRSA work comprises multiple BPA calls under three distinct Blanket Purchase Agreements with historical task orders ranging from $300 to $10,500; the largest HRSA vehicle is BPA 75R60219A00024, which has generated five task orders worth $21 thousand combined. Ducatman's most recent award is a May 28, 2026 purchase order from the Department of Justice for expert witness services valued at $169,100 with an ultimate completion date of February 1, 2031.

Ducatman's signature capability is medical expertise applied to vaccine injury case adjudication. The VICP portfolio spans case-specific medical review work (individual cases such as 17-1306, where Ducatman provided concurrent review orders ranging from $300 to $3,600 between January 2022 and December 2022) and broader expert testimony and case review services under an August 19, 2024 single-award BPA with HRSA valued at $7.5 million ceiling through August 18, 2029. A March 18, 2025 task order under that BPA was valued at $124,500. Recent activity is sparse — one award in 2026, one in 2025, two in 2024, and three in 2022 — with only $329 thousand obligated against $8.2 million in potential value, indicating slow task-order velocity against the standing HRSA agreements. Ducatman operates entirely as a prime contractor with no subcontract footprint. All fourteen awards are designated as small business work or full-and-open competitive, with no set-aside category concentration beyond the total small business mark applied to earlier VICP case calls.